Rakuten TV and Samsung TV Plus Reinforce Solid Partnership by Launching Over 166 Channels in 16 Markets
20.4.2021 11:30:00 EEST | Business Wire | Press release
Rakuten TV strengthens its ongoing partnership with Samsung Electronics to expand its free content offering on the platform’s AVOD (Advertising-Video-on-Demand) service and launches over 20 of the platform's own and third-party channels on the Samsung TV Plus service across 16 European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005300/en/
TV Plus Interface (Graphic: Business Wire)
This launch opens new opportunities for advertisers to get in front of audiences across the new regions added to the Samsung TV Plus service, in addition to the possibility of reaching wider audiences through the broadening of channel line-up in territories already live.
During April and May Rakuten TV will roll out a total of 166 new channels in 16 markets through TV Plus.
With 20 premium channels, Rakuten TV will provide the full channel line-up exclusively for TV Plus as it expands its service into new territories. The roll-out started today with the launch of new channels in Denmark, Finland and Norway, followed by Belgium, Luxembourg, Portugal and Ireland planned for May.
Rakuten TV has also landed today at TV Plus in Sweden and the Netherlands with the launch of 7 premium channels.
In addition, alongside Rakuten TV's line-up already live on TV Plus in the UK, Spain, Germany, France, Italy, Austria and Switzerland, the Family channel became available in these markets on 14 April.
This launch will also broaden opportunities for advertisers, by extending reach to audiences across Europe. Samsung TV Plus sits alongside Rakuten Advertising's integrated portfolio, where publishers and advertisers can place ad-inventory across a variety of channels with the potential to reach more than 27M users across Europe. Through Rakuten TV channels available on TV Plus, brands will be able to run targeted campaigns to reach their potential new customers leveraging Rakuten Advertising’s powerful set of 1st party data and audience insights.
The enhanced line-up will provide the highest quality content at no cost. From top global channels, such as Africanews, Bloomberg TV, Bloomberg Quicktake, Euronews—the first live channel integrated into Rakuten TV's AVOD offer—Reuters and VENN, to a wide range of Rakuten TV's own themed channels curated by genres, from Action, Comedy, Drama, Spotlight, Family and Documentaries.
The new channels will be available on the TV Plus service in Samsung Smart TV devices from 2016 onwards in the UK, Spain, Germany, France, Italy, Austria, Switzerland; and in Samsung Smart TV devices from 2017 onwards in the rest of the markets.
Click here to download image: https://rak.box.com/s/5q7midm7sjgq2ldy86fnjdw3xe0bg3oo
About Rakuten TV
Rakuten TV is the first Video-On-Demand platform in Europe combining TVOD (Transactional video-on-demand), AVOD (Advertising video-on-demand) and SVOD (Subscription video-on-demand) services, providing users with a universe of content just one click away. While Rakuten TV's TVOD service provides a true cinematic experience with the latest new releases, the AVOD service offers a range of thematic channels for free, including Movies, Euronews, Kids TV, Viki, Documentaries and Rakuten Stories - a channel embodying Rakuten TV's original and exclusive content. On the subscription side, the platform provides the international SVOD service, Starzplay, as a premium content provider of movies and TV series.
Rakuten TV is available in 43 European territories and forms part of Rakuten Group, Inc. one of the worlds’ leading internet services companies, offering a wide variety of services for consumers and businesses, with a focus on e-commerce, fintech and digital content. Rakuten, headquartered in Japan, is also known for its partnership with FC Barcelona, the NBA, the Golden State Warriors, Davis Cup and Spartan Race.
www.rakuten.tv
About Rakuten Advertising
Rakuten Advertising provides advertising technology and consumer insights to the world’s leading brands and retailers. Working with agencies and brands around the world, Rakuten Advertising unites technology, client strategy and consumer insights to deliver advertising experiences that drive increased brand awareness and marketing performance. With access to Rakuten’s global audiences, media, content networks and consumer research, Rakuten Advertising creates the right conditions to reach new customers and sustain long-lasting loyalty. It is a division of Rakuten Inc. (4755: TOKYO), one of the world’s leading Internet service companies. The company is headquartered in San Mateo, CA, with offices in Australia, Singapore, Brazil, France, Germany, Ukraine, the United Kingdom and throughout the United States. Learn more at https://rakutenadvertising.com/
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry, and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com
About TV Plus
Samsung TV Plus gives viewers instant access to top news, sports, entertainment, and more. It's 100% free and doesn't require any downloads, sign-up, credit cards, subscriptions or additional devices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005300/en/
Contact information
Rakuten TV
Fernanda Perabeles – PR & Communications Specialist - fernanda.perabeles@rakuten.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom